Fewer jabs GSK shares fell owing to a “disappointing” demand for its vaccines during the third quarter of this year. The ...
Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Moderna (MRNA) announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Hosted on MSN2d
Year in Review: RSVIn June, the FDA expanded the approval of GSK's RSV vaccine (Arexvy) to include adults ages 50-59 at increased risk of lower ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...
AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...
What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...
GlobalData on MSN4d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback